+1-518-618-1030 866 - 552 - 3453 USA-Canada Toll Free
Published Date: 2014-12-29Number of Pages: 74

CINV Existing and Pipeline Drugs Market (Aloxi, Zofran Generic, Kytril Generic, Emend, Akynzeo, SUSTOL and Rolapitant) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2017 - 2025

 
Chapter 1 Preface
1.1 Report Description
1.2 Market Segmentation
1.3 Research Methodology
      1.3.1 Assumptions
      1.3.2 Sources
              1.3.2.1 Secondary Research
              1.3.2.2 Primary Research
      1.3.3 Models
1.4 List of Abbreviations
 
Chapter 2 Executive Summary
2.1 Market Snapshot: Global CINV Existing and Pipeline Drugs Market (2013 & 2020)
2.2 Global CINV Drugs Market, by Major Drugs, 2013 (USD Million)
2.3 Comparative Analysis: Global CINV Drugs Market Revenue, by Geography, 2013 & 2020 (Value %)
 
Chapter 3 Global CINV Existing and Pipeline Drugs Market Overview
3.1 Chemotherapy Induced Nausea and Vomiting (CINV)
      3.1.1 Aetiology/Causes for CINV
      3.1.2 Pathogenesis of CINV
      3.1.3 Treatment Recommendations for CINV
      3.1.4 Unmet Needs in the CINV Market
3.2 Market Dynamics
      3.2.1 Drivers
               3.2.1.1 Growing number of patients undergoing chemotherapy
               3.2.1.2 Anticipated approval of new CINV drugs during the forecast period from 2014 to 2020
      3.2.2 Restraints
              3.2.2.1 Patent expirations of major CINV drugs during the projected period
              3.2.2.2 Strict regulatory pathway and high cost associated with the new drug discovery and development
      3.2.3 Opportunities
               3.2.3.1 Emphasis on developing breakthrough therapy for the prevention of CINV such as fixed-dose combination product and other innovative products with enhanced therapeutic efficacy
               3.2.3.2 Focusing on developing nations as they present immense market potential for CINV drugs
3.3 Event Impact Analysis
 
Chapter 4 Global CINV Existing and Pipeline Drugs Market Revenue, by Major Drugs, 2012 – 2020 (USD Million)
4.1 Overview
4.2 CINV Existing Drugs Market
      4.2.1 Global CINV Drugs Market Revenue, by Major Drugs, 2012 – 2020 (USD Million)
      4.2.2 Global CINV Estimated Patient Pool, by Major Drugs, 2012 – 2020 (Thousands)
      4.2.3 Comparative Analysis: Global CINV Drugs Market Revenue, by Major Drugs, 2013 & 2020 (Value %)
      4.2.4 Aloxi (palonosetron)
              4.2.4.1 Global Aloxi Market Revenue, 2012 – 2020 (USD Million)
      4.2.5 Zofran Generic (ondansetron)
              4.2.5.1 Global Zofran Generic Market Revenue, 2012 – 2020 (USD Million)
      4.2.6 Kytril Generic (granisetron)
              4.2.6.1 Global Kytril Generic Market Revenue, 2012 – 2020 (USD Million)
      4.2.7 Emend (aprepitant)
              4.2.7.1 Global Emend Market Revenue, 2012 – 2020 (USD Million)
      4.2.8 Akynzeo (netupitant-palonosetron FDC)
              4.2.8.1 Global Akynzeo Market Revenue, 2015 – 2020 (USD Million)
4.3 CINV Pipeline Drugs Market
      4.3.1 SUSTOL (granisetron injection extended release)
              4.3.1.1 Global SUSTOL Market Revenue, 2016 – 2020 (USD Million)
              4.3.1.2 SWOT Analysis for SUSTOL
              4.3.1.3 Overview of SUSTOL Phase III study
                         4.3.1.3.1 Primary Efficacy Results: Complete Response with Patients Receiving MEC
                         4.3.1.3.2 Primary Efficacy Results: Complete Response with Patients Receiving HEC
      4.3.2 Rolapitant
               4.3.2.1 Global Rolapitant Market Revenue, 2015 – 2020 (USD Million)
               4.3.2.2 SWOT Analysis for Rolapitant
               4.3.2.3 Overview of Rolapitant Efficacy Analysis
 
Chapter 5 Global CINV Existing and Pipeline Drugs Market Revenue, by Geography, 2012 – 2020 (USD Million)
5.1 Overview
      5.1.1 Global CINV Drugs Market Revenue, by Geography, 2012 – 2020 (USD Million)
      5.1.2 Global CINV Estimated Patient Pool, by Geography, 2012 – 2020 (Thousands)
5.2 North America
      5.2.1 North America CINV Drugs Market Revenue, 2012 - 2020 (USD Million)
      5.2.2 North America CINV Pipeline Drugs Market Revenue, 2015 – 2020 (USD Million)
      5.2.3 North America CINV Estimated Patient Pool, by Pipeline Drug, 2015 – 2020 (Thousands)
5.3 Europe
      5.3.1 Europe CINV Drugs Market Revenue, 2012 - 2020 (USD Million)
      5.3.2 Europe CINV Pipeline Drugs Market Revenue, 2016 – 2020 (USD Million)
      5.3.3 Europe CINV Estimated Patient Pool, by Pipeline Drug, 2016 – 2020 (Thousands)
5.4 Asia-Pacific
      5.4.1 Asia-Pacific CINV Drugs Market Revenue, 2012 - 2020 (USD Million)
5.5 Rest of the World (RoW)
      5.5.1 RoW CINV Drugs Market Revenue, 2012 - 2020 (USD Million)
 
Chapter 6 Competitive Landscape
6.1 Competitive Landscape
 
Chapter 7 Company Profiles
7.1 GlaxoSmithKline plc
      7.1.1 Company Overview
      7.1.2 Financial Overview
      7.1.3 Product Portfolio
      7.1.4 Business Strategies
      7.1.5 Recent Developments
7.2 Helsinn Holding S.A.
      7.2.1 Company Overview
      7.2.2 Financial Overview
      7.2.3 Product Portfolio
      7.2.4 Business Strategies
      7.2.5 Recent Developments
7.3 Heron Therapeutics, Inc.
      7.3.1 Company Overview
      7.3.2 Financial Overview
      7.3.3 Product Portfolio
      7.3.4 Business Strategies
      7.3.5 Recent Developments
7.4 Merck & Co., Inc.
      7.4.1 Company Overview
      7.4.2 Financial Overview
      7.4.3 Product Portfolio
      7.4.4 Business Strategies
      7.4.5 Recent Developments
7.5 Tesaro, Inc.
      7.5.1 Company Overview
      7.5.2 Financial Overview
      7.5.3 Product Portfolio
      7.5.4 Business Strategies
      7.5.5 Recent Developments

List of Figures
 
FIG. 1 CINV Existing and Pipeline Drugs: Market Segmentation
FIG. 2 Global CINV Drugs Market, by Major Drugs, 2013 (USD Million)
FIG. 3 Comparative Analysis: Global CINV Drugs Market Revenue, by Geography, 2013 & 2020 (Value %)
FIG. 4 Pathogenesis of CINV
FIG. 5 Unmet Needs in the CINV Market
FIG. 6 Comparative Analysis: Global CINV Drugs Market Revenue, by Major Drugs, 2013 & 2020 (Value %)
FIG. 7 Global Aloxi Market Revenue, 2012 – 2020 (USD Million)
FIG. 8 Global Zofran Generic Market Revenue, 2012 – 2020 (USD Million)
FIG. 9 Global Kytril Generic Market Revenue, 2012 – 2020 (USD Million)
FIG. 10 Global Emend Market Revenue, 2012 – 2020 (USD Million)
FIG. 11 Global Akynzeo Market Revenue, 2015 – 2020 (USD Million)
FIG. 12 Global SUSTOL Market Revenue, 2016 – 2020 (USD Million)
FIG. 13 Primary Efficacy Results: Complete Response with Patients Receiving MEC
FIG. 14 Primary Efficacy Results: Complete Response with Patients Receiving HEC
FIG. 15 Global Rolapitant Market Revenue, 2015 – 2020 (USD Million)
FIG. 16 North America CINV Drugs Market Revenue, 2012 – 2020 (USD Million)
FIG. 17 Europe CINV Drugs Market Revenue, 2012 – 2020 (USD Million)
FIG. 18 Asia-Pacific CINV Drugs Market Revenue, 2012 – 2020 (USD Million)
FIG. 19 RoW CINV Drugs Market Revenue, 2012 – 2020 (USD Million)

List of Tables
 
TABLE 1 List of Abbreviations
TABLE 2 Market Snapshot: Global CINV Existing and Pipeline Drugs Market (2013 & 2020)
TABLE 3 Chemotherapy Induced Nausea and Vomiting (CINV): Subtypes and Description
TABLE 4 Treatment Recommendations for CINV
TABLE 5 Event Impact Analysis: Global CINV Drugs Market
TABLE 6 Global CINV Drugs Market Revenue, by Major Drugs, 2012 – 2020 (USD Million)
TABLE 7 Global CINV Estimated Patient Pool, by Major Drugs, 2012 – 2020 (Thousands)
TABLE 8 SWOT Analysis for SUSTOL
TABLE 9 Efficacy of SUSTOL with Difficult Chemo Regimens
TABLE 10 SWOT Analysis for Rolapitant
TABLE 11 Overview of Rolapitant Efficacy Analysis
TABLE 12 Global CINV Drugs Market Revenue, by Geography, 2012 – 2020 (USD Million)
TABLE 13 Global CINV Estimated Patient Pool, by Geography, 2012 – 2020 (Thousands)
TABLE 14 North America CINV Pipeline Drugs Market Revenue, 2015 – 2020 (USD Million)
TABLE 15 North America CINV Estimated Patient Pool, by Pipeline Drug, 2015 – 2020 (Thousands)
TABLE 16 Europe CINV Pipeline Drugs Market Revenue, 2016 – 2020 (USD Million)
TABLE 17 Europe CINV Estimated Patient Pool, by Pipeline Drug, 2016 – 2020 (Thousands)
TABLE 18 GlaxoSmithKline plc: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 19 Helsinn Holding S.A.: Pipeline Product Portfolio
TABLE 20 Heron Therapeutics, Inc.: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 21 Heron Therapeutics, Inc.: Pipeline Product Portfolio
TABLE 22 Merck & Co., Inc.: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 23 Tesaro, Inc.: Expenses & Revenue, 2011 – 2013 (USD Million)
TABLE 24 Tesaro, Inc.: Pipeline Product Portfolio


 
 
Back To Top